This announcement is a separate document:
2023年浙江华康药业股份有限公司向不特定对象发行可转换公司债券2024年跟踪评级报告
In 2023, Zhejiang Huakang Pharmaceutical Co., Ltd. will issue convertible enterprise bonds to unspecified investors, and a follow-up credit rating report will be released in 2024.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.